[Current developments in prevention of coronary heart disease].
The Scandinavian Simvastatin Survival Study (4S-Studie) has provided proof beyond any doubt that reduction of plasma cholesterol decreases mortality. The enormous rise of morbidity and mortality from cardiovascular disease in both gender calls for preventative measures as an urgent task. With a reduction of cardiac events by 30-40% and of mortality in the same order of magnitude, cholesterol lowering and increase in HDL-cholesterol are most effective measures for the treatment of coronary artery disease. However, not treatment of late stages of the disease, but primary prevention to reduce the incidence of coronary artery disease in this country should be the principle aim. Thus, the international guidelines for the treatment of lipid disorders considering the individual patient's risk profile have been revised.
Windler
E
E
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg.
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage / Q000009:adverse effects; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D019821:Simvastatin; D015996:Survival Rate
D000924:Anticholesteremic Agents; D002791:Cholesterol, Dietary; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin
Aktuelle Entwicklungen in der Prävention der koronaren Herzkrankheit.